199 related articles for article (PubMed ID: 38684865)
1. Identification and affinity enhancement of T-cell receptor targeting a KRAS
Zhang M; Xu W; Luo L; Guan F; Wang X; Zhu P; Zhang J; Zhou X; Wang F; Ye S
Commun Biol; 2024 Apr; 7(1):512. PubMed ID: 38684865
[TBL] [Abstract][Full Text] [Related]
2. Targeting KRAS
Ai Q; Li F; Zou S; Zhang Z; Jin Y; Jiang L; Chen H; Deng X; Peng C; Mou N; Wen C; Shen B; Zhan Q
Front Immunol; 2023; 14():1161538. PubMed ID: 37287989
[TBL] [Abstract][Full Text] [Related]
3. KRAS G12V neoantigen specific T cell receptor for adoptive T cell therapy against tumors.
Lu D; Chen Y; Jiang M; Wang J; Li Y; Ma K; Sun W; Zheng X; Qi J; Jin W; Chen Y; Chai Y; Zhang CWH; Liang H; Tan S; Gao GF
Nat Commun; 2023 Oct; 14(1):6389. PubMed ID: 37828002
[TBL] [Abstract][Full Text] [Related]
4. High-affinity oligoclonal TCRs define effective adoptive T cell therapy targeting mutant KRAS-G12D.
Sim MJW; Lu J; Spencer M; Hopkins F; Tran E; Rosenberg SA; Long EO; Sun PD
Proc Natl Acad Sci U S A; 2020 Jun; 117(23):12826-12835. PubMed ID: 32461371
[TBL] [Abstract][Full Text] [Related]
5. [Preclinical study of T cell receptor specifically reactive with
Cheng XJ; Jiang D; Zhang LH; Wang JH; Li YZ; Zhai JH; Yan BQ; Zhang LL; Xie XW; Li ZY; Ji JF
Beijing Da Xue Xue Bao Yi Xue Ban; 2022 Oct; 54(5):884-895. PubMed ID: 36241231
[TBL] [Abstract][Full Text] [Related]
6. Identification of T-cell Receptors Targeting KRAS-Mutated Human Tumors.
Wang QJ; Yu Z; Griffith K; Hanada K; Restifo NP; Yang JC
Cancer Immunol Res; 2016 Mar; 4(3):204-14. PubMed ID: 26701267
[TBL] [Abstract][Full Text] [Related]
7. Therapeutic high affinity T cell receptor targeting a KRAS
Poole A; Karuppiah V; Hartt A; Haidar JN; Moureau S; Dobrzycki T; Hayes C; Rowley C; Dias J; Harper S; Barnbrook K; Hock M; Coles C; Yang W; Aleksic M; Lin AB; Robinson R; Dukes JD; Liddy N; Van der Kamp M; Plowman GD; Vuidepot A; Cole DK; Whale AD; Chillakuri C
Nat Commun; 2022 Sep; 13(1):5333. PubMed ID: 36088370
[TBL] [Abstract][Full Text] [Related]
8. In vitro proteasome processing of neo-splicetopes does not predict their presentation in vivo.
Willimsky G; Beier C; Immisch L; Papafotiou G; Scheuplein V; Goede A; Holzhütter HG; Blankenstein T; Kloetzel PM
Elife; 2021 Apr; 10():. PubMed ID: 33875134
[TBL] [Abstract][Full Text] [Related]
9. Identification of neoepitope reactive T-cell receptors guided by HLA-A*03:01 and HLA-A*11:01 immunopeptidomics.
Ade CM; Sporn MJ; Das S; Yu Z; Hanada KI; Qi YA; Maity T; Zhang X; Guha U; Andresson T; Yang JC
J Immunother Cancer; 2023 Sep; 11(9):. PubMed ID: 37758652
[TBL] [Abstract][Full Text] [Related]
10. Targeting KRAS mutations with HLA class II-restricted TCRs for the treatment of solid tumors.
Dillard P; Casey N; Pollmann S; Vernhoff P; Gaudernack G; Kvalheim G; Wälchli S; Inderberg EM
Oncoimmunology; 2021; 10(1):1936757. PubMed ID: 34235003
[TBL] [Abstract][Full Text] [Related]
11. Facts and Hopes in Immunotherapy Strategies Targeting Antigens Derived from KRAS Mutations.
Linette GP; Bear AS; Carreno BM
Clin Cancer Res; 2024 May; 30(10):2017-2024. PubMed ID: 38266167
[TBL] [Abstract][Full Text] [Related]
12. An
Mishto M; Mansurkhodzhaev A; Ying G; Bitra A; Cordfunke RA; Henze S; Paul D; Sidney J; Urlaub H; Neefjes J; Sette A; Zajonc DM; Liepe J
Front Immunol; 2019; 10():2572. PubMed ID: 31803176
[TBL] [Abstract][Full Text] [Related]
13. Identification of an HLA-A*11:01-restricted neoepitope of mutant PIK3CA and its specific T cell receptors for cancer immunotherapy targeting hotspot driver mutations.
Shen M; Chen S; Han X; Hao Y; Wang J; Li L; Chen T; Wang B; Zou L; Zhang T; Zhang W; Han X; Wang W; Yu H; Li K; Liu S; Jin A
Cancer Immunol Immunother; 2024 Jun; 73(8):150. PubMed ID: 38832948
[TBL] [Abstract][Full Text] [Related]
14. Structural basis for T cell recognition of cancer neoantigens and implications for predicting neoepitope immunogenicity.
Mariuzza RA; Wu D; Pierce BG
Front Immunol; 2023; 14():1303304. PubMed ID: 38045695
[TBL] [Abstract][Full Text] [Related]
15. Rational discovery of a cancer neoepitope harboring the KRAS G12D driver mutation.
Bai P; Zhou Q; Wei P; Bai H; Chan SK; Kappler JW; Marrack P; Yin L
Sci China Life Sci; 2021 Dec; 64(12):2144-2152. PubMed ID: 33740187
[TBL] [Abstract][Full Text] [Related]
16. KRAS G12V mutation upregulates PD-L1 expression via TGF-β/EMT signaling pathway in human non-small-cell lung cancer.
Pan LN; Ma YF; Li Z; Hu JA; Xu ZH
Cell Biol Int; 2021 Apr; 45(4):795-803. PubMed ID: 33325140
[TBL] [Abstract][Full Text] [Related]
17. Higher metastatic efficiency of KRas G12V than KRas G13D in a colorectal cancer model.
Alamo P; Gallardo A; Di Nicolantonio F; Pavón MA; Casanova I; Trias M; Mangues MA; Lopez-Pousa A; Villaverde A; Vázquez E; Bardelli A; Céspedes MV; Mangues R
FASEB J; 2015 Feb; 29(2):464-76. PubMed ID: 25359494
[TBL] [Abstract][Full Text] [Related]
18. An Efficient Single-Cell RNA-Seq Approach to Identify Neoantigen-Specific T Cell Receptors.
Lu YC; Zheng Z; Robbins PF; Tran E; Prickett TD; Gartner JJ; Li YF; Ray S; Franco Z; Bliskovsky V; Fitzgerald PC; Rosenberg SA
Mol Ther; 2018 Feb; 26(2):379-389. PubMed ID: 29174843
[TBL] [Abstract][Full Text] [Related]
19. Endogenous CD4
Veatch JR; Jesernig BL; Kargl J; Fitzgibbon M; Lee SM; Baik C; Martins R; Houghton AM; Riddell SR
Cancer Immunol Res; 2019 Jun; 7(6):910-922. PubMed ID: 31043415
[TBL] [Abstract][Full Text] [Related]
20. Hydrophobic interactions dominate the recognition of a KRAS G12V neoantigen.
Wright KM; DiNapoli SR; Miller MS; Aitana Azurmendi P; Zhao X; Yu Z; Chakrabarti M; Shi W; Douglass J; Hwang MS; Hsiue EH; Mog BJ; Pearlman AH; Paul S; Konig MF; Pardoll DM; Bettegowda C; Papadopoulos N; Kinzler KW; Vogelstein B; Zhou S; Gabelli SB
Nat Commun; 2023 Aug; 14(1):5063. PubMed ID: 37604828
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
